Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-27
2008-05-27
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S013800, C514S015800, C514S016700, C514S017400, C514S018700, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000
Reexamination Certificate
active
11198005
ABSTRACT:
The present invention provides methods and agents for treating subjects who have or are at risk of developing or having cardiovascular disease. Such agents inhibit binding of myeloperoxidase (MPO) to a molecule comprising the MPO binding site of apolipoprotein A-1 (apoA-1) and include a peptide fragment of apoA-1 comprising at least 4 contiguous amino acids in SEQ ID. NO: 2, a modified form of the apo-1 fragment comprising one or more D amino acids, a retro-inverso form of the apoA-1 peptide fragment, an organo-mimetic of the apoA-1 peptide fragment, a peptide-mimetic of the apoA1 peptide fragment, or a nucleic acid encoding the apo A-1 peptide fragment. The present invention also provides methods of identifying or screening test agents for treating subjects having or at risk of having or developing CVD. The method comprises incubating one or more test agents and MPO with a molecule comprising the MPO binding site of apoA-1 under conditions which permit binding of MPO to the MPO binding site and determining whether one or more of the agents inhibit such binding.
REFERENCES:
patent: 5122534 (1992-06-01), Loose et al.
patent: 5731208 (1998-03-01), Heinecke
patent: 5747274 (1998-05-01), Jackowski
patent: 5889042 (1999-03-01), MacLean et al.
patent: 5962636 (1999-10-01), Bachmaier et al.
patent: 5985272 (1999-11-01), Deby et al.
patent: 6040147 (2000-03-01), Ridker et al.
patent: 6096556 (2000-08-01), Heinecke
patent: 6133039 (2000-10-01), Heinecke
patent: 6268220 (2001-07-01), Heinecke
patent: 6953666 (2005-10-01), Kinkade, Jr. et al.
patent: 7223552 (2007-05-01), Hazen et al.
patent: 2002/0156007 (2002-10-01), Graverson et al.
patent: 2002/0164662 (2002-11-01), Hazen et al.
patent: 2003/0008373 (2003-01-01), Bartel et al.
patent: 2003/0045004 (2003-03-01), Barri et al.
patent: 2003/0045460 (2003-03-01), Fogelman et al.
patent: 2003/0119792 (2003-06-01), Roca
patent: 2003/0180218 (2003-09-01), Hazen
patent: 2004/0029807 (2004-02-01), Dasseux et al.
patent: 2005/0202532 (2005-09-01), Bielicki et al.
patent: 2006/0051873 (2006-03-01), FitzGerald
patent: 2006/0079475 (2006-04-01), Zhang et al.
patent: 01/38395 (2001-05-01), None
patent: 02/50550 (2002-06-01), None
patent: 0248715 (2002-06-01), None
patent: 02062207 (2002-08-01), None
patent: 03/023397 (2003-03-01), None
patent: WO 2005/061539 (2005-07-01), None
“Oxidized LDL and HDL: antagonists in atherothrombosis” by Mertens, et al., FASEB J., 15, 2073-2084 (2001).
“Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species” by Podrez, et al., J. Clin. Ivest. 105:1095-1108 (2000).
“Kinetics of Oxidation of Tyrosine and Dityrosine by Myeloperoxidase Compounds I and II” by Marquez, et al., The Journal of Biological Chemistry, vol. 270, No. 51, Dec. 22, 1995, pp. 30434-30440.
“Leukocytes Utilize Myeloperoxidase-Generated Nitrating Intermediates as Physiological Catalysts for the Generation of Biologically Active Oxidized Lipids and Sterols in Serum” by Schmitt, et al., Biochemistry, 1999, 38, 16904-16915.
“Nitric Oxide Modulates the Catalytic Activity of Myeloperoxidase” by Abu-Soud, et al., The Journal of Biological Chemistry, vol. 275, No. 8, Feb. 25, 2000, pp. 5425-5430.
“Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall” by Heinecke, et al., FASEB J., 13, 1113-1120 (1999).
“Myeloperoxidase-Generated Oxidants and Atherosclerosis” by Podrez, et al., Free Radical Biology & Medicine, vol. 28, No. 12, pp. 1717-1725, Jan. 2000.
“Myeloperoxidase, a Catalyst for Lipoprotein Oxidation, Is Expressed in Human Atherosclerosis Lesions” by Daugherty, et al., J. Clin. Invest., vol. 94, Jul. 1994, 437-444.
“3-Chlorotyrosine, a Specific Marker of Myeloperoxidase-catalyzed Oxidation, Is Markedly Elevated in Low Density Lipoprotein Isolated from Human Atherosclerosis Intima” by Hazen, et al., J. Clin. Invest., vol. 99, No. 9, May 1997, 2075-2081.
Elevated levels of protein-bound p-hydroxyphenylacetaldehyde, an amino acid-derived aldehyde generated by myeloperoxidase, are present in hun fatty streaks, intermediate lesions and advanced atherosclerosis lesions by Hazen, et al., Biochem J. (2000) 352, 693-699.
“p-Hydroxypheylacetaldehyde, an Aldehyde Generated by Myeloperoxidase, Modifies Phospholipid Amino Groups of Low Density Lipoprotein in Human Atherosclerosis Intima” by Heller, et al., The Journal of Biological Chemistry, vol. 275, No. 14, Apr. 7, 2000, pp. 9957-9962.
“Is the Oxidative Modification Hypothesis Relevant to Human Atherosclerosis? Do the Antioxidant Trials Conducted to Date Refute the Hypothesis?” by Steinberg, et al., Circulation, 2002; 105:2107-2111.
“Human Phagocytes Employ the Myeloperoxidase-Hydrogen Peroxide System to Synthesize Dityrosine, Trityrosine, Pulcherosine, and Isodityrosine by a Tyrosol Radical-dependent Pathway” by Jacob, et al., The Journal of Biological Chemistry, vol. 271, No. 33, Aug. 16, 1996, pp. 19950-19956.
“Kinetics of tryptophan oxidation in plasma lipoproteins by myeloperoxidase-generated HOCI” by Jerlich, et al., Eur. J. Biochem., 267, 4137-4143 (2000).
“Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro” by Podrez, et al., The Journal of Clinical Investigation, Jun. 1999, vol. 103, No. 11, pp. 1547-1560.
“Formation of Nitric-Oxide Derived Oxidants by Myeloperoxidase in Monocytes, Pathways for Monocyte-Mediated Protein Nitration and Lipid Peroxidation In Vivo” by Hazen, et al., Circ Res. 1999; 85:950-958.
International Search Report Dated Oct. 12, 2005.
“Arg123-Tyr166 Domain of Human ApoA-1 Is Critical for HDL-Mediated Inhibition of Macrophage Homing and Early Atherosclerosis in Mice” by Holvoet, et al., Arterioscler Thromb Vasc Biol., Dec. 2001, pp. 1977-1983.
U.S. Appl. No. 10/972,058, filed Oct. 22, 2004, entitled: Assessing the Risk of a Major Cardiac Event in Patients with Chest Pain.
U.S. Appl. No. 10/417,838, filed Apr. 17, 2003, entitled: Systemic Marker for Monitoring Anti-Inflammatory and Antioxidant Actions of Therapeutic Agents.
U.S. Appl. No. 11/412,065, filed Apr. 26, 2006, entitled: Systemic Marker for Monitoring Anti-Inflammatory and Antioxidant Actions of Therapeutic Agents.
U.S. Appl. No. 11/313,012, filed Dec. 20, 2005, entitled: Myeloperoxidase, A Risk Indicator for Cardiovascular Disease.
U.S. Appl. No. 11/005,563, filed Dec. 6, 2004, entitled: Risk Markers for Cardiovascular Disease.
Office Action dated Mar. 21, 2007, for U.S. Appl. No. 11/005,563, filed Dec. 6, 2004, entitled: Risk Markers for Cardiovascular Disease.
Supplementary Partial European Search Report dated May 31, 2007.
“Association of Nitrotyrosine Levels With Cardivascular Disease and Modulation by Statin Therapy” by Shishehbor, et al., JAMA 2003;289:1675-1680.
“Associations between change in C-reactive protein and serum lipids during statin treatment” by Strandberg, et al., Ann Med 2000;32:579-583.
“Effects of Low Doses of Simvastatin and Atrovastatin on High-Density Lipoprotein Cholesterol Levels in Patients with Hypercholesterolemia” by Branchi, et al., Clinical Therapeutics, vol. 23, No. 6, 2001, pp. 851-857.
“Modification of Proteins and Lipids by Myeloperoxidase” by Hazen, et al., Methods in Enzymology, vol. 300, pp. 89-105. (1999).
“Mechanisms of oxidative damage by myeloperoxidase in atherosclerosis and other inflammatory disorders” by Heinecke, J Lab Clin Med 1999;133:321-5.
“The Oxidative Modification Hypothesis of Atherogenesis: An Overview” by Chisolm, et al., Free Radical Biology & Medicine, vol. 28, No. 12, pp. 1815-1826, 2000.
“Myeloperoxidase binds to low-denisity lipoprotein: potential implications for atherosclerosis” by Carr, et al., FEBS Letters, 487 (2000) 176-
Hazen Stanley L.
Penn Marc S.
Calfee Halter & Griswold LLP
Russel Jeffrey Edwin
The Cleveland Clinic Foundation
LandOfFree
Therapeutic agents and methods for cardiovascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents and methods for cardiovascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents and methods for cardiovascular disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3930139